Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
methylphenidate
|
| gptkbp:availableSizes |
100 mg/5 mL
|
| gptkbp:brand |
gptkb:Quillivant_XR
Quillivant |
| gptkbp:clinicalTrials |
Phase 3
|
| gptkbp:colors |
orange
|
| gptkbp:contraindication |
glaucoma
heart problems history of substance abuse |
| gptkbp:date |
FDA_approved
|
| gptkbp:dosageForm |
liquid
|
| gptkbp:drugInterdiction |
true
stimulant |
| gptkbp:duration |
up to 12 hours
|
| gptkbp:endOfLife |
approximately 3.5 hours
|
| gptkbp:flavorProfile |
cherry
|
| gptkbp:formFactor |
oral suspension
|
| gptkbp:formulation |
suspension
|
| gptkbp:gestationPeriod |
C
|
| gptkbp:hasPopulation |
children and adolescents
|
| gptkbp:healthcare |
important for effectiveness
|
| https://www.w3.org/2000/01/rdf-schema#label |
Quillivant XR
|
| gptkbp:impact |
as prescribed by a doctor
|
| gptkbp:inheritsFrom |
1 to 2 hours
|
| gptkbp:interactsWith |
gptkb:MAO_inhibitors
antidepressants antihypertensives |
| gptkbp:is_monitored_by |
weight
blood pressure heart rate |
| gptkbp:lastProduced |
2013
|
| gptkbp:manufacturer |
gptkb:Neos_Therapeutics
|
| gptkbp:packaging |
bottle
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
not for use in patients with a history of tics
not for use in patients with agitation not for use in patients with hyperthyroidism not for use in patients with severe anxiety |
| gptkbp:sideEffect |
anxiety
nausea decreased appetite insomnia dry mouth |
| gptkbp:storage |
room temperature
|
| gptkbp:symptoms |
depression
fatigue sleep disturbances |
| gptkbp:type |
methylphenidate
|
| gptkbp:usedFor |
treatment of ADHD
|